Recombinant Tumor Suppressor ARF (CDKN2A) (full length) antibody

Catalog No. ABIN7879269

The Rabbit Monoclonal anti-Tumor Suppressor ARF antibody is suitable to detect Tumor Suppressor ARF in samples from Human. It has been validated for IHC (p).

Quick Overview for Recombinant Tumor Suppressor ARF (CDKN2A) (full length) antibody (ABIN7879269)

Target: Tumor Suppressor ARF (CDKN2A)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CDKN2A-8196R

Product Details

Binding Specificity: full length

Purpose: P16INK4a Antibody / Cyclin-dependent kinase inhibitor 2A Antibody / CDKN2A

Purification: Protein A/G affinity

Immunogen: Purified recombinant prokaryotic full-length human protein was used as the immunogen for the P16INK4a antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the P16INK4a antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Aliquot the P16INK4a antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details

Target: Tumor Suppressor ARF (CDKN2A)

Alternative Name: P16INK4a / Cyclin-dependent kinase inhibitor 2A

Background: P16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.

UniProt: P42771